AH 111585 clinical trials
Also written Fluciclatide.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses AH 111585 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- Fluciclatide
- 3
Studies by the year they started
5 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
GE Healthcare (2) · National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1)
Studies
Open first, then newest update. How each study uses AH 111585 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Imaging Studies and the Development of Multiple MyelomaWithdrawnPhase 2National Cancer Institute (NCI)NCT01571726Written as FluciclatideHow we know
- A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid TumorsWithdrawnPhase 1/2National Cancer Institute (NCI)NCT01176500Written as (18)FluciclatideHow we know
- A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and AngiogenesisCompletedPhase 2GE HealthcareNCT00565721Written as Fluciclatide Injection - (AH111585 (F18))How we know
- A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer TherapyWithdrawnPhase 1M.D. Anderson Cancer CenterNCT02193672Written as [18F] FluciclatideHow we know
- Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) InjectionCompletedPhase 2GE HealthcareNCT00918281Written as Fluciclatide InjectionHow we know